tenkasi (previously orbactiv)
menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakterielle midler til systemisk brug, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
selexid 200 mg filmovertrukne tabletter
karo pharma ab - pivmecillinamhydrochlorid - filmovertrukne tabletter - 200 mg
selexid 200 mg filmovertrukne tabletter
orifarm a/s - pivmecillinamhydrochlorid - filmovertrukne tabletter - 200 mg
talzenna
pfizer europe ma eeig - talazoparib - bryst neoplasmer - antineoplastiske midler - talzenna er angivet som monoterapi til behandling af voksne patienter med germline brca1/2 mutationer, der har her2-negative lokalt fremskreden eller metastatisk brystkræft. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patienter med hormon receptor (hr)-positiv brystkræft skulle have været behandlet med en forudgående endokrine-baseret terapi, eller anses uegnet til at endokrine-baseret terapi.
azithromycin "stada" 500 mg filmovertrukne tabletter
stada arzneimittel ag - azithromycinmonohydrat - filmovertrukne tabletter - 500 mg
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - ef-erhvervede infektioner - antibakterielle midler til systemisk brug, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
xenleta
nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakterielle midler til systemisk brug, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
azithromycin "orifarm" 500 mg filmovertrukne tabletter
orifarm generics a/s - azithromycindihydrat - filmovertrukne tabletter - 500 mg
azithromycin "stada" 40 mg/ml pulver til oral suspension
stada arzneimittel ag - azithromycindihydrat - pulver til oral suspension - 40 mg/ml
dalacin 150 mg/ml injektionsvæske, opløsning
pfizer aps - clindamycinphosphat - injektionsvæske, opløsning - 150 mg/ml